Drug news
Betaconnect filed with FDA for Multiple Sclerosis-Bayer
The FDA has accepted the filing for Bayer's supplemental Biologics License Application (sBLA) for Betaconnect (proposed name), another delivery option for Betaseron (interferon beta-1b), a treatment for relapsing-remitting multiple sclerosis.
Betaseron (interferon beta-1b) is a "biologic" medication that is controlled under a different set of rules and laws than most other drugs. These laws currently prevent any biologic medications from being manufactured in generic form.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.